Yazar "Harmankaya, Ismail" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Effects of Adipose-Derived Stem Cells and Platelet-Rich Plasma for Prevention of Alopecia and Other Skin Complications of Radiotherapy
    (Lippincott Williams & Wilkins, 2021) Evin, Nuh; Tosun, Zekeriya; Aktan, Tahsin Murad; Duman, Selcuk; Harmankaya, Ismail; Yavas, Guler
    Background Radiotherapy (RT) involves the use of ionizing radiation in treating malignancies and benign disorders. However, RT damages target and healthy surrounding tissues in a dose-dependent manner. This effectively reduces patient compliance and quality of life, thereby warranting the prevention of RT-induced adverse effects on skin. Adipose-derived stem cells (ASCs) are used to treat RT-induced damage and platelet-rich plasma (PRP) provides a scaffold that potentiates the effects of ASCs. Thus, the aim of this study was to determine the mechanism employed by ASCs and PRP in protecting against RT-induced adverse effects. Methods We have established an immunodeficient mouse transplantation model using which human hair follicular units were implanted. When the follicular units were macroscopically and microscopically mature and anagenic, we administered localized RT. Subsequently, the mice were randomly divided into 4 groups based on the subcutaneous injection of the following to the irradiated transplantation site: saline, PRP, ASCs, and a combination of ASCs and PRP. Next, we used macroscopic and microscopic analyses to determine the protective effects of the injected solutions on skin and hair follicles. Results Adipose-derived stem cells reduced RT-induced adverse effects, such as impaired wound healing, alopecia, skin atrophy, and fibrosis by suppressing inflammation, dystrophy, degeneration, connective tissue synthesis, and apoptosis and increasing cellular proliferation, differentiation, and signaling. Moreover, these effects were augmented by PRP. Conclusions Thus, co-administering ASCs with PRP in mice prevented RT-induced adverse effects and can be tested for use in clinical practice.
  • Küçük Resim Yok
    Öğe
    Pilomatrixoma in childhood
    (Medknow Publications & Media Pvt Ltd, 2014) Kose, Dogan; Ciftci, Ilhan; Harmankaya, Ismail; Ugras, Serdar; Caliskan, Umran; Koksal, Yavuz
    Context: Pilomatrixoma is a benign tumor of the skin. Malignant transformation can be seen rarely in the small percentage. Aim: The aim of the following study is to attract attention to this tumor in the differential diagnosis because if it is not kept in mind it leads to both unnecessary interventions and treatments for the patient. Patients and Methods: From January 2006 to December 2012, 8 patients with pilomatrixoma were evaluated retrospectively. Results: A total of 8 pediatric pilomatrixoma patients charts were reviewed retrospectively. None of the patients had familial feature. Of 8 patients 4 (50%) were male and 4 (50%) were female. The patients age ranged from 2-18 years with a median age 11.5 years. All of the patients were admitted with the complaint of swelling at the lesion site. Two patients have multiple lesions, one of them has two and other has three lesions. A total of 11 lesion were detected in our 8 patients that 5 of them were located upper extremities (46%), 3 of them cervical region (27%), 2 of them on occipital region (18%) and 1 of them in the sacral region (9%). All lesions were excised completely. Until now, no patient had evidence of recurrence or malignant disease. Conclusion: As a result pilomatrixoma is a benign tumor, with atypical forms and unfortunately, no tumor-specific diagnostic feature except of a careful histopathological examination is available.
  • Küçük Resim Yok
    Öğe
    The Role of Stem Cells Derived From the Mesenchyme of the Umbilical Cord in Reducing Immunosuppressive Drug Doses Used in Allogenic Transplantations
    (Lippincott Williams & Wilkins, 2022) Evin, Seyda Guray; Sutcu, Mustafa; Aktan, Tahsin Murad; Duman, Selcuk; Harmankaya, Ismail; Abusoglu, Sedat
    BackgroundThis study evaluated the potential of Wharton's jelly mesenchymal stem cells with high tolerogenic properties in reducing immunosuppressive dosage and related adverse effects.MethodsA 4- to 6-week-old, 30-40 g weight, male inbred CD57BL/6 mice were used as skin allograft donors, whereas Balb/c mice with similar characteristics were used as recipients. Wharton's jelly stem cells were obtained from a commercial kit sourced from human umbilical cord. Skin allografts were performed from CD57Bl6 to Balb/c mice (day 0). Group 1 (control) received no treatment. Group 2 received 15 mg/kg cyclosporin A on days 0 to 30. Group 3 received 5.7 x 10(6) and 10.3 x 10(6) cell/kg Wharton's jelly stem cells on days 0 and 3, respectively. Groups 4, 5, and 6 received a combination of 15, 10, and 5 mg/kg per day cyclosporine A (days 0 to 30) with the same stem cell dose with group 3, respectively. Graft rejection was evaluated with digital photography and thermal imaging, histopathology (Banff grading, epithelialization scores, dermoepidermal dissociation), immunochemistry (Ki-67 and Bcl-2), and biochemical methods (interleukin 10, interleukin 2, interferon gamma, tumor necrosis factor alpha) (day 10). Cumulative adverse effects of cyclosporin A occurring in the groups were revealed by histopathological evaluation of kidney and liver (a modified semiquantitative method of infiltration of inflammatory cells around the portal area and lobular region in liver; modification of the Banff rating of proximal tubules and hypertrophia of juxtaglomerular apparatus cells in kidney) (day 30).ResultsThere was no rejection in groups 2, 4, and 5 until the end of study. These were statistically different versus groups 1 (day 10 +/- 0.71), 3 (day 11 +/- 0.82), and 6 (day 11 +/- 0.58) (all P's < 0.05). Groups 4 and 5 have exhibited statistically similar findings in histopathological (4 epithelization score: 3.7 +/- 1.3; 5 epithelization score: 3.5 +/- 0.5; 4 Banff grading score: 0.8 +/- 0.6; 5 Banff grading score: 1.0 +/- 0.5; both P's = 1.00), immunohistochemical (4 Bcl-2 score: 3.5 +/- 0.5, P = 0.618; 5 Bcl-2 score: 3.4 +/- 0.5, P = 1.00; 4 Ki-67 score: 3.7 +/- 0.4, P = 1.00; 5 Ki-67 score: 3.5 +/- 0.5, both P's = 1.00), and levels of cytokines (both P's = 1.00) versus group 2. Adverse effects on kidneys and liver were lowest and statistically similar in groups 3, 5, and 6 (all P's = 00) versus group 1.ConclusionsWharton's jelly mesenchymal stem cells alter bioavailability of cyclosporine, albeit at much lower doses and with fewer systemic adverse effects.